Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.75 |
| ▸ | ITK | Q08881 | 7/20 | 0.75 |
| ▸ | BTK | Q06187 | 5/20 | 0.56 |
| ▸ | SYK | P43405 | 2/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | BLK | P51451 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14769220 | 0.90 | EGFR (0.62) | EGFRITKBTK | |
| SCHEMBL14771996 | 0.87 | BTK (0.72) | EGFRITKBTKFLT3BLK | |
| SCHEMBL14769165 | 0.86 | BTK (0.66) | EGFRITKBTK | |
| SCHEMBL12518559 | 0.86 | EGFR (1.00) | EGFRITKBTKSYK | |
| SCHEMBL29722450 | 0.86 | EGFR (1.00) | EGFRITKBTKSYK | |
| SCHEMBL12518584 | 0.84 | ITK (1.00) | EGFRITKBTK | |
| SCHEMBL29722282 | 0.84 | ITK (1.00) | EGFRITKBTK | |
| SCHEMBL18165632 | 0.79 | EGFR (0.86) | EGFRITKBTK | |
| SCHEMBL12519537 | 0.78 | ITK (0.87) | EGFRITKBTK | |
| SCHEMBL21109653 | 0.78 | ITK (0.84) | EGFRITKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710222-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710222-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ITK 2697/4885BTK 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.